Galectin-3 in patients with atrial fibrillation undergoing radiofrequency catheter ablation.
BACKGROUND:Galectin-3 (Gal-3) is an emerging biomarker in heart failure that is involved in fibrosis and inflammation. However, its potential value as a prognostic marker in atrial fibrillation (AF) is unknown. The aim of this study was to assess the impact of AF catheter ablation on Gal-3 and evalu...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4398460?pdf=render |
id |
doaj-9a7665eadfc040ac9a9bbec52b56a845 |
---|---|
record_format |
Article |
spelling |
doaj-9a7665eadfc040ac9a9bbec52b56a8452020-11-24T21:50:34ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01104e012357410.1371/journal.pone.0123574Galectin-3 in patients with atrial fibrillation undergoing radiofrequency catheter ablation.Jelena KornejJosephin SchmidlLaura UeberhamSilke JohnSait DaneschnejadBorislav DinovGerhard HindricksVolker AdamsDaniela HusserAndreas BollmannBACKGROUND:Galectin-3 (Gal-3) is an emerging biomarker in heart failure that is involved in fibrosis and inflammation. However, its potential value as a prognostic marker in atrial fibrillation (AF) is unknown. The aim of this study was to assess the impact of AF catheter ablation on Gal-3 and evaluate its prognostic impact for predicting rhythm outcome after catheter ablation. METHODS:Gal-3 was measured at baseline and after 6 months using specific ELISA. AF recurrences were defined as any atrial arrhythmia lasting longer than 30 sec within 6 months after ablation. RESULTS:In 105 AF patients (65% males, age 62±9 years, 52% paroxysmal AF) undergoing catheter ablation, Gal-3 was measured at baseline and after 6 months and compared with an AF-free control cohort (n=14, 50 % males, age 58±11 years). Gal-3 was higher in AF patients compared with AF-free controls (7.8±2.9 vs. 5.8±1.8, ng/mL, p=0.013). However, on multivariable analysis, BMI (p=0.007) but not AF (p=0.068) was associated with Gal-3. In the AF cohort, on univariable analysis higher Gal-3 levels were associated with female gender (p=0.028), higher BMI (p=0.005) and both CHADS2 (p=0.008) and CHA2DS2-VASC (p=0.016) scores, however, on multivariable analysis only BMI remained significantly associated with baseline Gal-3 (p=0.016). Gal-3 was similar 6 months after AF catheter ablation and was not associated with sinus rhythm maintenance. CONCLUSIONS:Although galectin-3 levels are higher in AF patients, this is driven by cardiometabolic co-morbidities and not heart rhythm. Gal-3 is not useful for predicting rhythm outcome of catheter ablation.http://europepmc.org/articles/PMC4398460?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jelena Kornej Josephin Schmidl Laura Ueberham Silke John Sait Daneschnejad Borislav Dinov Gerhard Hindricks Volker Adams Daniela Husser Andreas Bollmann |
spellingShingle |
Jelena Kornej Josephin Schmidl Laura Ueberham Silke John Sait Daneschnejad Borislav Dinov Gerhard Hindricks Volker Adams Daniela Husser Andreas Bollmann Galectin-3 in patients with atrial fibrillation undergoing radiofrequency catheter ablation. PLoS ONE |
author_facet |
Jelena Kornej Josephin Schmidl Laura Ueberham Silke John Sait Daneschnejad Borislav Dinov Gerhard Hindricks Volker Adams Daniela Husser Andreas Bollmann |
author_sort |
Jelena Kornej |
title |
Galectin-3 in patients with atrial fibrillation undergoing radiofrequency catheter ablation. |
title_short |
Galectin-3 in patients with atrial fibrillation undergoing radiofrequency catheter ablation. |
title_full |
Galectin-3 in patients with atrial fibrillation undergoing radiofrequency catheter ablation. |
title_fullStr |
Galectin-3 in patients with atrial fibrillation undergoing radiofrequency catheter ablation. |
title_full_unstemmed |
Galectin-3 in patients with atrial fibrillation undergoing radiofrequency catheter ablation. |
title_sort |
galectin-3 in patients with atrial fibrillation undergoing radiofrequency catheter ablation. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2015-01-01 |
description |
BACKGROUND:Galectin-3 (Gal-3) is an emerging biomarker in heart failure that is involved in fibrosis and inflammation. However, its potential value as a prognostic marker in atrial fibrillation (AF) is unknown. The aim of this study was to assess the impact of AF catheter ablation on Gal-3 and evaluate its prognostic impact for predicting rhythm outcome after catheter ablation. METHODS:Gal-3 was measured at baseline and after 6 months using specific ELISA. AF recurrences were defined as any atrial arrhythmia lasting longer than 30 sec within 6 months after ablation. RESULTS:In 105 AF patients (65% males, age 62±9 years, 52% paroxysmal AF) undergoing catheter ablation, Gal-3 was measured at baseline and after 6 months and compared with an AF-free control cohort (n=14, 50 % males, age 58±11 years). Gal-3 was higher in AF patients compared with AF-free controls (7.8±2.9 vs. 5.8±1.8, ng/mL, p=0.013). However, on multivariable analysis, BMI (p=0.007) but not AF (p=0.068) was associated with Gal-3. In the AF cohort, on univariable analysis higher Gal-3 levels were associated with female gender (p=0.028), higher BMI (p=0.005) and both CHADS2 (p=0.008) and CHA2DS2-VASC (p=0.016) scores, however, on multivariable analysis only BMI remained significantly associated with baseline Gal-3 (p=0.016). Gal-3 was similar 6 months after AF catheter ablation and was not associated with sinus rhythm maintenance. CONCLUSIONS:Although galectin-3 levels are higher in AF patients, this is driven by cardiometabolic co-morbidities and not heart rhythm. Gal-3 is not useful for predicting rhythm outcome of catheter ablation. |
url |
http://europepmc.org/articles/PMC4398460?pdf=render |
work_keys_str_mv |
AT jelenakornej galectin3inpatientswithatrialfibrillationundergoingradiofrequencycatheterablation AT josephinschmidl galectin3inpatientswithatrialfibrillationundergoingradiofrequencycatheterablation AT lauraueberham galectin3inpatientswithatrialfibrillationundergoingradiofrequencycatheterablation AT silkejohn galectin3inpatientswithatrialfibrillationundergoingradiofrequencycatheterablation AT saitdaneschnejad galectin3inpatientswithatrialfibrillationundergoingradiofrequencycatheterablation AT borislavdinov galectin3inpatientswithatrialfibrillationundergoingradiofrequencycatheterablation AT gerhardhindricks galectin3inpatientswithatrialfibrillationundergoingradiofrequencycatheterablation AT volkeradams galectin3inpatientswithatrialfibrillationundergoingradiofrequencycatheterablation AT danielahusser galectin3inpatientswithatrialfibrillationundergoingradiofrequencycatheterablation AT andreasbollmann galectin3inpatientswithatrialfibrillationundergoingradiofrequencycatheterablation |
_version_ |
1725883092137148416 |